Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(57.1%)
Phase 1
2(28.6%)
Phase 3
1(14.3%)
7Total
Phase 4(4)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00015301Phase 4Completed

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

Role: collaborator

NCT00015171Phase 3Completed

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

Role: collaborator

NCT00015249Phase 1Completed

Prepulse Inhibition of Startle in Cocaine Dependence - 7

Role: collaborator

NCT00015275Phase 4Completed

Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9

Role: collaborator

NCT00015340Phase 4Completed

Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14

Role: collaborator

NCT00015236Phase 4Completed

Modeling Impaired Judgement in Cocaine Abusers - 6

Role: collaborator

NCT00015288Phase 1Completed

Buprenorphine and Naloxone Combination Study - 10

Role: collaborator

All 7 trials loaded